

Q2 2023 Business and Financial Presentation



August 8, 2023

Forward-looking statements and non-GAAP information

This presentation contains forward-looking statements, including, but not limited to, our statements related to our expected total revenue for 2023 and other financial and operating results and our plans, objectives, expectations (financial and otherwise) or intentions with respect to our tests and products, including our biopharma atlas, for use in diagnosing and treating diseases, and our commercial organization. Forward-looking statements can be identified by words such as: "appears," "anticipate," "intend," "plan," "expect," "believe," "should," "may," "will," "positioned," "designed" and similar references to future periods. Actual results may differ materially from those projected or suggested in any forward-looking statements. These statements involve risks and uncertainties, which could cause actual results to differ materially from our predictions, and include, but are not limited to: our ability to launch, commercialize and receive reimbursement for our products; to demonstrate the validity and utility of our genomic tests and biopharma offerings; to continue to integrate and expand the HalioDx and Decipher businesses and execute on our business plans; to continue to scale our global operations and enhance our internal control environment; the impact of the war in Ukraine on European economies and energy supply, as well as our facilities in France; the impact of the COVID-19 pandemic and its variants on our business and general economic conditions; the impact of foreign currency fluctuations, increasing interest rates, and inflation, and turnoil in the global banking and finance system; and the performance and utility of our tests in the clinical environment. Additional factors that may impact these forward-looking statements in our Annual Report on Form 10-K filed for the year ended December 31, 2022, and our Quarterly Report on Four 10-Q for the three months ended June 30, 2023, to be filed with the Securities and Exchange Commission. Copies of these documents, when available, may be found in the In

In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), this presentation contains certain non-GAAP results including non-GAAP gross margin, non-GAAP operating expenses, and non-GAAP loss from operations. These measures are not meant to be considered superior to or a substitute for financial measures calculated in accordance with GAAP, and investors are cautioned that there are material limitations associated with the use of non-GAAP financial measures as an analytical tool. We use non-GAAP measures to internally evaluate and analyze financial results. We believe these non-GAAP financial measures provide investors with useful supplemental information about the financial performance of our business, enable comparison of financial results between periods where certain items may vary independent of business performance, and enable comparison of our financial results with other public companies, many of which present similar non-GAAP financial measures. However, the non-GAAP measures we present may be different from those used by other companies.

We exclude amortization of acquired intangible assets, acquisition-related expenses relating to our acquisitions of Decipher Biosciences and HalioDx and costs related to restructuring from certain of our non-GAAP measures. Management has excluded the effects of these items in non-GAAP measures to help investors gain a better understanding of the core operating results and future prospects of the company, consistent with how management measures and forecasts the company's performance, especially when comparing such results to previous periods or forecasts. The company encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand its business. Reconciliations between our GAAP results and non-GAAP financial measures are presented in the Appendix.

Veracyte, the Veracyte logo, Decipher, Afirma, Percepta, Envisia, Prosigna, Lymphmark, TMExplore, Brightplex, Immunosign, "Know by Design" and "More about You" are registered trademarks of Veracyte, Inc. and its subsidiaries in the U.S. and selected countries. Immunoscore IC® is a trademark of Veracyte SAS registered in France. Immunoscore is a registered trademark of Inserm used by Veracyte under license. nCounter is the registered trademark of NanoString Technologies used by Veracyte under license.

Key Q2 2023 Results and FY 2023 Outlook

- 1. Strong Q2 2023 revenue of \$90.3M driven by Decipher Prostate and Afirma
- Ended Q2 with \$191M of cash,¹ and generated ~\$17M of cash from operations during the quarter
- 3. Presented 12 abstracts on our diagnostic tests and biopharmaceutical offerings, demonstrating our commitment to advance the scientific understanding of diseases we address
- Raised 2023 revenue guidance to \$342M to \$350M² based on testing revenue growth in the mid-twenties
- 1. As of June 30, 2023, includes cash, cash equivalents and short-term investments
- 2. Guidance as of August 8, 2023 only; assumes currency exchange rates as of August 8, 2023





Our vision is to transform cancer care for patients all over the world.



OUR PURPOSE

We believe exceptional cancer care begins with exceptional diagnostics

OUR PROMISE

We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer



Our proven framework for developing successful tests

1


Identify clinical unmet needs

through collaboration with customers. We focus on oncology where we help inform diagnosis, prognosis and treatment decisions

2

Develop highperformance tests

using deep scientific, clinical and machinelearning expertise and capabilities




IDENTIFY

3

Drive adoption

through KOL support, evidence development, guideline inclusion, reimbursement and market development


Delivered Q2 total revenue growth of 24%



Amounts in millions; Testing, Product and BioPharma and Other revenue rounded and summarized as presented


Q2 2023 NON-GAAP GROSS MARGIN AND OPERATING EXPENSE

Strong Non-GAAP gross margin



Non-GAAP Gross Margin by Quarter¹

Non-GAAP Operating Expense by Quarter^{1,2}




1. Non-GAAP reconciliations available in the appendix of this presentation

2. Amounts in millions; Operating expenses rounded and summarized as presented


Cash balance of \$191M¹

- Record Q2 cash generated by operations of \$16.7M
- Testing growth and working capital performance resulted in higher than projected cash balance
- 2023 outlook:
 - Raising expectations for ending 2023 cash balance to \$190M²



- 1. Ending balance of cash, cash equivalents and short-term investments, excluding restricted cash, in millions
- 2. Guidance as of August 8, 2023, reposting should not be considered a reiteration of guidance; excludes the impact of potential M&A

Raising 2023 revenue guidance to \$342M to \$350M



- Testing, Product and Biopharma and other revenue rounded and summarized as presented in millions 1.
- Guidance and currency rates are as of August 8, 2023; reposting should not be considered a reiteration of guidance 2.
- 2021 included \$4M JNJ milestone 3.

\$19M



2023 GUIDANCE

Increased guidance in revenue and cash

	Updated Guidance ¹	Prior Guidance ²
Total revenue	\$342M - \$350M	\$330M - \$340M
Testing revenue growth	Mid-twenties	Mid-to-high teens
Afirma revenue growth	Low-to-mid teens	High-single digits
Biopharma and other revenue	\$18M - \$19M 📕	
Gross margin	Mid-to-high 60's	Mid-60's
2023 Ending Cash ³	\$190M including contingent consideration ⁴	~\$180M including contingent consideration ⁴

- 1. Guidance and currency rates are as of August 8, 2023, reposting should not be considered a reiteration of guidance
- 2. Prior guidance provided on May 4, 2023
- 3. Cash, cash equivalents and short-term investments, excludes the impact of potential M&A
- 4. The impact of prior acquisition related contingent consideration payments

(Unaudited)

(In thousands of dollars)

				ld						
		_	Acquisition Rel	Acquisition Related Intangible Assets						
	GAAP		Expenses (1)		Amortization Expense		(Other (4)	Total Non-GA	AP Measure
Three Months Ended June 30, 2023										
Total revenue	\$	90,322	\$		\$		\$	—	\$	90,322
Cost of testing revenue		23,333				_		_		23,333
Cost of product revenue		2,315				_		_		2,315
Cost of biopharmaceutical and other revenue		4,040		25				_		4,015
Intangible asset amortization (2)		4,814		_		4,814		_		, <u> </u>
Gross margin \$		55,820		25		4,814				60,659
Gross margin %		62 %								67 %
Research and development		12,541		17				_		12,524
Selling and marketing		25,756		889		_		_		24,867
General and administrative		25,047		1,720				1,437		21,890
Intangible asset amortization		527				527				
Total operating expenses excluding cost of revenue										
(3)		63,871		2,626		527		1,437		59,281
		<i>/~ ~ ~ / </i>								
Loss from operations	\$	(8,051)	\$	2,651	\$	5,341	\$	1,437		<u> </u>

1. Includes transaction related expenses as well as post-combination compensation expenses. For each of the three months ended June 30, 2022, and June 30, 2023, adjustments consist primarily of post-combination compensation expenses associated with the acquisition of HalioDx.

2. Includes only amortization of intangible assets identified as developed technology assets through purchase accounting transactions, which otherwise would have been allocated to cost of revenue.

3. Includes only amortization of intangible assets, which otherwise would have been allocated to research and development, selling and marketing or general and administrative expense and excludes the cost of revenue (\$29.7 million and \$25.0 million) and the amortization of intangible assets which would have been allocated to the cost of revenue (\$4.8 million and \$4.9 million) for the three months ended June 30, 2023 and for the three months ended June 30, 2023 and for the three months ended June 30, 2022 respectively.

4. For the three months ended June 30, 2022, \$3.3 million expense included related to the impairment charge associated with certain developed technology intangible assets. For the three months ended June 30, 2023, includes \$1.4 million related to the departure of the former executive chair.

(Unaudited)

(In thousands of dollars)

			ld						
	_								
GAA	GAAP		Expenses (1)		Amortization Expense		Other (4)	Total Non-GAA	P Measure
\$	82,422	\$	—	\$	—	\$	—	\$	82,422
	19,648		83		_		_		19,565
	2,162		_		_		_		2,162
	4,419		43		_		_		4,376
	4,804		_		4,804		_		·
	51,389		126		4,804				56,319
	62 %								68 %
	12.769		24		_		_		12,745
	•				_		_		25,240
	•				_		1.344		20,083
	525				525				
	61,887		1,950		525		1,344		58,068
\$	(10 498)	\$	2 076	\$	5 329	\$	1 344	\$	(1,749)
	GAA \$ 	\$ 82,422 19,648 2,162 4,419 4,804 51,389 62 % 12,769 26,130 22,463 525 61,887	GAAP Expenses (\$ 82,422 \$ 19,648 2,162 4,419 4,804 4,804 4,804 51,389 62 % 62,130 22,463 525 525	Acquisition Related Expenses (1) \$ 82,422 \$ 19,648 83 2,162 4,419 43 4,804 51,389 126 62 % 890 22,463 1,036 525 61,887 1,950	Acquisition Related Expenses (1) Intang Amortiza \$ 82,422 \$ \$ 19,648 \$ 83 2,162 - 4,419 43 43 4,804 - 51,389 126 62 % 12,769 24 26,130 890 22,463 1,036 - 61,887 1,950 -	GAAP Expenses (1) Amortization Expense \$ 82,422 \$ \$ 19,648 83 2,162 4,419 43 4,804 4,804 51,389 126 4,804 62 % 12,769 24 26,130 890 22,463 1,036 525 525 61,887 1,950 525	Acquisition Related Expenses (1) Intangible Assets Amortization Expense \$ 82,422 \$ \$ \$ 19,648 \$ 2,162 \$ \$ 4,419 \$ 4,804 \$ 4,804 \$ 4,804 \$ 4,804 \$ 4,804 \$ 4,804 \$ 4,804 \$ 4,804 \$ 4,804 \$ 4,804 \$ 4,804	$\begin{tabular}{ c c c c c c c c c c c } \hline Acquisition Related Expenses (1) & Intangible Assets Amortization Expense & Other (4) \\ \hline Acquisition Related Expenses (1) & Amortization Expense & Other (4) \\ \hline & & & & & & & & & & & & & & & & & &$	Acquisition Related Expenses (1)Intangible Assets Amortization ExpenseOther (4)Total Non-GAA\$ 82,422\$\$\$\$19,648 83 2,1624,419434,8044,80451,3891264,80462 %22,4631,03622,4631,0361,34452552561,8871,9505251,344

1. Includes transaction related expenses as well as post-combination compensation expenses, adjustments consist primarily of post-combination compensation expenses associated with the acquisition of HalioDx.

2. Includes only amortization of intangible assets identified as developed technology assets through purchase accounting transactions, which otherwise would have been allocated to cost of revenue.

3. Includes only amortization of intangible assets, which otherwise would have been allocated to research and development, selling and marketing or general and administrative expense and excludes the cost of revenue (\$26.2 million) and the amortization of intangible assets which would have been allocated to the cost of revenue (\$4.8 million).

4. Includes impairment charge associated with Richmond.

(Unaudited)

(In thousands of dollars)

				ld					
		_	Acquisition Re	lated	Intang	ible Assets			
	GAAP		Expenses (1)		Amortization Expense		Other	Total Non-GAAF	Measure
Three Months Ended December 31, 2022									
Total revenue	\$	80,297	\$		\$	—	\$ —	\$	80,297
Cost of testing revenue		19,394		50		—	—		19,344
Cost of product revenue		2,618				—	—		2,618
Cost of biopharmaceutical and other revenue		4,819		64		—	—		4,755
Intangible asset amortization (2)		4,747				4,747	_		·
Gross margin \$		48,719		114		4,747	_		53,580
Gross margin %		61 %							67 %
Research and development		11,287		232		_	_		11,055
Selling and marketing		24,127		917		_	_		23,210
General and administrative		18,208		1,368		_	_		16,840
Intangible asset amortization		517				517	—		
Total operating expenses excluding cost of revenue									
(3)		54,139		2,517		517	_		51,105
	¢	(5.400)	¢	0.004	¢	5.004	¢	¢	0 475
Income (loss) from operations	>	(5,420)	\$	2,631	<u> </u>	5,264	<u> </u>		2,475

1. Includes transaction related expenses as well as post-combination compensation expenses consisting primarily of post-combination compensation expenses associated with the acquisition of HalioDx.

2. Includes only amortization of intangible assets identified as developed technology assets through purchase accounting transactions, which otherwise would have been allocated to cost of revenue.

3. Includes only amortization of intangible assets, which otherwise would have been allocated to research and development, selling and marketing or general and administrative expense and excludes the cost of revenue (\$26.8 million) and the amortization of intangible assets which would have been allocated to the cost of revenue (\$4.7 million).

(Unaudited)

(In thousands of dollars)

				ld					
		Acquisition Related Intangible Assets							
	GAAP		Expenses (1)		Amortization Expense		Other (4)	Total Non-GAAF	Measure
Three Months Ended September 30, 2022									
Total revenue	\$	75,592	\$	—	\$	—	\$ —	\$	75,592
Cost of testing revenue		19,816		49		—	18		19,749
Cost of product revenue		1,981				—	3		1,978
Cost of biopharmaceutical and other revenue		4,211		62		—	_		4,149
Intangible asset amortization (2)		4,703		_		4,703	_		·
Gross margin \$		44,881		111		4,703	21		49,716
Gross margin %		59 %							66 %
Research and development		10,773		251		_	_		10,552
Selling and marketing		25,678		923		_	493		24,262
General and administrative		17,600		1,272		_			16,328
Intangible asset amortization		510		, 		510			
Total operating expenses excluding cost of revenue									
(3)		54,561		2,446		510	493		51,112
	•	(0,000)	^	0 557	۴	5.040	ф с ()	^	(4,000)
Loss from operations	\$	(9,680)	\$	2,557	<u> </u>	5,213	\$ 514	\$	(1,396)

1. Includes transaction related expenses as well as post-combination compensation expenses consisting primarily of post-combination compensation expenses associated with the acquisition of HalioDx.

2. Includes only amortization of intangible assets identified as developed technology assets through purchase accounting transactions, which otherwise would have been allocated to cost of revenue.

3. Includes only amortization of intangible assets, which otherwise would have been allocated to research and development, selling and marketing or general and administrative expense and excludes the cost of revenue (\$26.0 million) and the amortization of intangible assets which would have been allocated to the cost of revenue (\$4.7 million).

4. Includes \$0.5 million expense related to restructuring costs.

(Unaudited)

(In thousands of dollars)

	GAAP		Acquisition Related Expenses (1)		Intangible Assets Amortization Expense		011			
							Other (4)	Total Non-GAAP Measure		
Three Months Ended June 30, 2022										
Total revenue	\$	72,864	\$	_	\$	—	\$ —	\$	72,864	
Cost of testing revenue		18,584		51		—	—		18,533	
Cost of product revenue		1,646		_		—	—		1,646	
Cost of biopharmaceutical and other revenue		4,800		65		_	_		4,735	
Intangible asset amortization (2)		4,869		_		4,869	—		—	
Gross margin \$		42,965		116		4,869	—		47,950	
Gross margin %		59 %							66 %	
Research and development		9,377		293		—	_		9,084	
Selling and marketing		24,001		858		—	_		23,143	
General and administrative		19,798		(285)		_	3,318		16,765	
Intangible asset amortization		522				522	—			
Total operating expenses excluding cost of revenue										
(3)		53,698		866		522	3,318		48,992	
Income (loss) from operations	\$	(10,733)	\$	982	\$	5,391	\$ 3,318	\$	(1,042)	

1. Includes transaction related expenses as well as post-combination compensation expenses consisting primarily of post-combination compensation expenses associated with the acquisition of HalioDx.

2. Includes only amortization of intangible assets identified as developed technology assets through purchase accounting transactions, which otherwise would have been allocated to cost of revenue.

3. Includes only amortization of intangible assets, which otherwise would have been allocated to research and development, selling and marketing or general and administrative expense and excludes the cost of revenue (\$25.0 million) and the amortization of intangible assets which would have been allocated to the cost of revenue (\$4.9 million).

4. Includes \$3.3 million expense related to the impairment charge associated with certain developed technology intangible assets.